Guidelines for the management of nilotinib (Tasigna®)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)

被引：8
作者：
Etienne, G. [2 ,7 ]
Milpied, B. [3 ]
Rea, D. [4 ,7 ]
Rigal-Huguet, F. [5 ,7 ]
Tulliez, M. [6 ,7 ]
Nicolini, F. -E. [1 ,7 ]
机构：
[1] Hop Edouard Herriot, Serv Hematol Clin, F-69437 Lyon 03, France
[2] Ctr Reg Lutte Canc, Inst Bergonie, F-33076 Bordeaux, France
[3] Hop St Andre, Serv Dermatol, F-33075 Bordeaux, France
[4] Hop St Louis, AP HP, Serv Malad Sang, F-75475 Paris 15, France
[5] Hop Purpan, Serv Hematol Clin, F-31300 Toulouse, France
[6] Hop Henri Mondor, AP HP, Serv Hematol Biol, F-94000 Creteil, France
[7] CHU La Miletrie, Fi LMC, F-86021 Poitiers, France
来源：
BULLETIN DU CANCER | 2010年 / 97卷 / 08期
关键词：
CML; imatinib; nilotinib; TKI2; side effects; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; IMATINIB-RESISTANT; FORMERLY AMN107; PREGNANCY;
D O I：
10.1684/bdc.2010.1136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nilotinib (Tasigna (R)) is a second-generation BCR-ABL kinase inhibitor, recently introduced and used for the treatment of chronic or accelerated phase CML patients, intolerant or resistant to imatinib. This treatment represents and important step forward for the disease control of such patients but can lead to side effects, sometimes serious, which can limit its optimal use. We propose here some guidelines that might be of help in daily practice, in order to manage properly these side effects.
引用
收藏
页码：997 / 1009
页数：13
相关论文
共 22 条
  • [1] Pregnancy among patients with chronic myeloid leukemia treated with imatinib
    Ault, P
    Kantarjian, H
    O'Brien, S
    Faderl, S
    Beran, M
    Rios, MB
    Koller, C
    Giles, F
    Keating, M
    Talpaz, M
    Cortes, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1204 - 1208
  • [2] Baccarani M, 2008, BLOOD, V112, P172
  • [3] Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study
    Conchon, Monika
    Sanabani, Sabri S.
    Bendit, Israel
    Santos, Fernanda Maria
    Serpa, Mariana
    Dorliac-Llacer, Pedro Enrique
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
  • [4] Guidelines for the management of dasatinib (Sprycelr)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias
    Cony-Makhoul, Pascale
    Begeron, Anne
    Corm, Selim
    Dubruille, Viviane
    Rea, Delphine
    Rigal-Huguet, Francoise
    Nicolini, Franck Emmanuel
    [J]. BULLETIN DU CANCER, 2008, 95 (09) : 805 - 811
  • [5] *FDA, 2009, PRESCR INF AOUT
  • [6] The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
    Garg, Ravin J.
    Kantarjian, Hagop
    O'Brien, Susan
    Quintas-Cardama, Alfonso
    Faderl, Stefan
    Estrov, Zeev
    Cortes, Jorge
    [J]. BLOOD, 2009, 114 (20) : 4361 - 4368
  • [7] JABBOUR E, 2008, BLOOD, V112
  • [8] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Kantarjian, Hagop
    Giles, Francis
    Wunderle, Lydia
    Bhalla, Kapil
    O'Brien, Susan
    Wassmann, Barbara
    Tanaka, Chiaki
    Manley, Paul
    Rae, Patricia
    Mietlowski, William
    Bochinski, Kathy
    Hochhaus, Andreas
    Griffin, James D.
    Hoelzer, Dieter
    Albitar, Maher
    Dugan, Margaret
    Cortes, Jorge
    Alland, Leila
    Ottmann, Oliver G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) : 2542 - 2551
  • [9] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Kantarjian, Hagop M.
    Giles, Francis
    Gattermann, Norbert
    Bhalla, Kapil
    Alimena, Giuliana
    Palandri, Francesca
    Ossenkoppele, Gert J.
    Nicolini, Franck-Emmanuel
    O'Brien, Stephen G.
    Litzow, Mark
    Bhatia, Ravi
    Cervantes, Francisco
    Haque, Ariful
    Shou, Yaping
    Resta, Debra J.
    Weitzman, Aaron
    Hochhaus, Andreas
    le Coutre, Philipp
    [J]. BLOOD, 2007, 110 (10) : 3540 - 3546
  • [10] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
123